Official Statement, Stock Price Movements, and Public Offering of Common Stock - Research Report on Amgen, Biogen Idec, Express Scripts, Endo, and CSI PR Newswire NEW YORK, November 26, 2013 NEW YORK, November 26, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Amgen, Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Express Scripts Holding Company (NASDAQ: ESRX), Endo Health Solutions Inc. (NASDAQ: ENDP), and Cardiovascular Systems Inc. (NASDAQ: CSII). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Amgen, Inc. Research Report On November 21, 2013, Amgen, Inc. (Amgen) published a statement regarding a misleading note issued by the biotech analyst at Bank of America Merrill Lynch, after a dinner meeting with Celgene management. According to Amgen, in its follow up with Celgene, they acknowledged citing anecdotal reports from high volume multiple myeloma centers of cardiovascular (CV) events with Kyprolis, a product that Onyx holds global rights to, but also clarified that Celgene made no representation of the event rates being any different than what is already included in the Kyprolis label. Amgen informed that the Phase 3 Kyprolis trials are monitored and safety data are reviewed regularly by independent Data Monitoring Committees (DMCs), and no DMCs have reported any specific safety concerns and have recommended continuing the Phase 3 studies, to date. Amgen reported that The Bank of America Merrill Lynch note incorrectly characterizes confidential information on event rates during the course of the ASPIRE study, which are not shared with Celgene as part of the supply agreement. Amgen added that its post-marketing reporting and on-going clinical data have not revealed any new safety concerns. The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/e96b_AMGN Biogen Idec Inc. Research Report On November 21, 2013, Biogen Idec Inc. (Biogen Idec)'s stock rose 2.56%, ending the day at $252.43. Over the previous three trading sessions, shares of Biogen Idec rose 4.63% compared to the Nasdaq Composite which gained 0.51% during the same period. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/b95b_BIIB Express Scripts Holding Company Research Report On November 21, 2013, Express Scripts Holding Company's (Express Scripts) stock rose 1.08%, ending the day at $65.88. Over the previous three trading sessions, shares of Express Scripts gained 1.37% compared to the Nasdaq Composite which gained 0.51% over the same period. The Full Research Report on Express Scripts Holding Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/91a7_ESRX Endo Health Solutions Inc. Research Report On November 19, 2013, Endo Health Solutions Inc. (Endo) announced that the Company has commenced consent solicitations with respect to proposed amendments to the indentures governing its senior notes listed, which include 7% Senior Notes due 2019, 7.00% Senior Notes due 2020, and 7¼% Senior Notes due 2022, subject to the terms and conditions set forth in the Consent Solicitation Statement, dated November 19, 2013 (the Statement). Endo stated that it is soliciting consents from holders of record of each series of Notes as of 5:00 p.m., New York City time, on the day of the release, to certain proposed amendments to each of the indentures governing the Notes. Endo added that subject to the terms and conditions set forth in the Statement, it will pay eligible holders who validly deliver and do not revoke their consents on or prior to 5:00 p.m. New York City time, on November 27, 2013, as may be extended by Endo with respect to one or more series of the Notes in accordance with the Statement, a cash payment equal to $2.50 per $1,000 aggregate principal amount of each series of Notes consented. The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/059c_ENDP Cardiovascular Systems Inc. Research Report On November 20, 2013, Cardiovascular Systems Inc. (CSI) announced the pricing of an underwritten public offering of approximately 2.6 million shares of common stock, at a price to the public of $30.00 per share. CSI reported that it expects the net proceeds from the sale of the shares, after deducting underwriting discounts and commissions and estimated expenses, of approximately $73.4 million. Further, CSI informed that all of the shares in the offering are to be sold by CSI. The Company is expecting the offer to close on or about November 26, 2013. The Company added that CSI granted the underwriters a 30-day option to purchase up to an additional 391,304 shares. The Full Research Report on Cardiovascular Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/11b9_CSII EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com/ SOURCE Analysts' Corner Contact: Joe Thomas, +1-310-496-8071 (North America)
Official Statement, Stock Price Movements, and Public Offering of Common Stock - Research Report on Amgen, Biogen Idec, Express
Press spacebar to pause and continue. Press esc to stop.